{"product_id":"cst-20485s","title":"CST,  20485S, Total ALK Matched Antibody Pair","description":"Matched Antibody Pair for studying ALK in the research area.\n\n\u003cb\u003eProduct Usage Information\u003c\/b\u003e\nMatched Antibody Pairs consist of capture and detection antibodies that bind to non-overlapping epitopes. For specific identification of the capture and detection antibodies in this pair, please refer to the data figure caption. Optimal dilutions\/concentrations should be determined by the end user.\n\u003cb\u003eFormulation\u003c\/b\u003e\nSupplied in 1X PBS (10 mM Na 2 HPO 4 , 3 mM KCl, 2 mM KH 2 PO 4 , and 140 mM NaCl (pH 7.8)). BSA and Azide Free.\n\u003cb\u003eStorage\u003c\/b\u003e\nStore at -20ºC. This product will freeze at -20ºC so it is recommended to aliquot into single-use vials to avoid multiple freeze\/thaw cycles . A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance.\n\u003cb\u003eBackground\u003c\/b\u003e\nAnaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor for pleiotrophin (PTN), a growth factor involved in embryonic brain development (1-3). In ALK-expressing cells, PTN induces phosphorylation of both ALK and the downstream effectors IRS-1, Shc, PLCγ, and PI3 kinase (1). ALK was originally discovered as a nucleophosmin (NPM)-ALK fusion protein produced by a translocation (4). Investigators have found that the NPM-ALK fusion protein is a constitutively active, oncogenic tyrosine kinase associated with anaplastic lymphoma (4). Research literature suggests that activation of PLCγ by NPM-ALK may be a crucial step for its mitogenic activity and involved in the pathogenesis of anaplastic lymphomas (5). A distinct ALK oncogenic fusion protein involving ALK and echinoderm microtubule-associated protein like 4 (EML4) has been described in the research literature from a non-small cell lung cancer (NSCLC) cell line, with corresponding fusion transcripts present in some cases of lung adenocarcinoma. The short, amino-terminal region of the microtubule-associated protein EML4 is fused to the kinase domain of ALK (6-8). Investigators have identified ALK translocations with other fusion partners, such as TRK-fused gene (TFG) and KIF5B, which have also been associated with NSCLC (6,7). In particular, the EML4-ALK fusion protein has been found in 3-7% of NSCLC samples (6-14).\n\u003cb\u003eAlternate Names\u003c\/b\u003e\nALK; ALK receptor tyrosine kinase; ALK tyrosine kinase receptor; Anaplastic lymphoma kinase; anaplastic lymphoma receptor tyrosine kinase; CD246; CD246 antigen; mutant anaplastic lymphoma kinase; NBLST3\n\n\u003cb\u003eSpecification\u003c\/b\u003e\n\nREACTIVITY: H","brand":"CST","offers":[{"title":"Default Title","offer_id":46800305488041,"sku":"20485S","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/cst-20485s","provider":"Iright","version":"1.0","type":"link"}